Future microbiology
-
Future microbiology · Jan 2015
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Isavuconazole is the first broad spectrum prodrug triazole with efficacy against invasive fungal diseases including aspergillosis and mucormycosis. Characteristics include linear dose-proportional pharmacokinetics, intravenous and oral formulations allowing therapeutic streamlining, once daily dosing, absence of nephrotoxic solubilizing agents and excellent oral bioavailability independent of prandial status and gastric acidity. An open label noncomparator study demonstrated encouraging results for isavuconazole as primary or salvage therapy for a range of fungi including mucormycosis. ⋯ Cross-resistance of isavuconazole best correlates with voriconazole. In vitro resistance is not invariably predictive of clinical failure. Isavuconazole signals progress in pharmacokinetics, bioavailability and toxicity/tolerability supported by clinical efficacy from Phase III trials.
-
Future microbiology · Jan 2015
Antimicrobial activity and resistance selection of different bioglass S53P4 formulations against multidrug resistant strains.
This study aimed to evaluate the antimicrobial activity of two different formulations of bioglass BAG-S53P4 against multiresistant microorganisms involved in bone infections, and the capability of bioglass to select for resistance. ⋯ BAG-S53P4 has a significant potential as bone substitute for the treatment of infections caused by multiresistant microorganisms.
-
Future microbiology · Jan 2015
Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
High rates of morbidity and mortality have been linked to the emergence of antimicrobial-resistant Gram-negative pathogens, especially in the hospital setting. Infections due to extended-spectrum-β-lactamase producing Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae) and multidrug-resistant Pseudomonas aeruginosa pose a major health threat and dramatically reduce the therapeutic options to achieve an appropriate treatment. ⋯ Phase II and III trials have shown high efficacy and good tolerability in complicated urinary and intra-abdominal infections compared with standard therapy. A study for the treatment of nosocomial pneumonia is planned.
-
Future microbiology · Jan 2015
Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.
The aim was to assess the distribution of nontuberculous mycobacteria (NTM) in treated patients with pulmonary disease (PD) in Greece. ⋯ The increasing number of NTM PD in Greece is a consequence of their isolation being more frequently considered as clinically relevant.